The Patent Finder

Eureka Therapeutics, Inc.

39 patents currently held · Updated Nov 18, 2026
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 28, 2026
    The maintenance fee for Antibody agents specific for human CD19 and uses thereof (US 10,301,388) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
  • 1 fee due Dec 13, 2026
    The maintenance fee for Anti-ROR2 Antibodies (US 11,673,957) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
  • 1 fee due Jan 7, 2027
    The maintenance fee for T Cell Receptor-Like Antibodies Specific for a Wti Peptide Presented by HLA-A2 (US 9,074,000) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
  • 1 fee due Feb 15, 2027
    The maintenance fee for Antibodies Targeting B-Cell Maturation Antigen and Methods of Use (US 11,725,059) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
  • 3 fees due May 5 to 28, 2027 · next May 5
  • 1 fee due Jun 10, 2027
    The maintenance fee for T Cell Receptor-Like Antibody Agents Specific for Ebv Latent Membrane Protein 2A Peptide Presented by Human Hla (US 10,501,559) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
  • 1 fee due Jul 9, 2027
    The maintenance fee for Nucleic Acid Molecules Encoding Chimeric Antigen Receptors Targeting G-Protein Coupled Receptor (US 11,866,478) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
  • 1 fee due Aug 18, 2027
    The maintenance fee for Antibodies Targeting B-Cell Maturation Antigen and Methods of Use (US 10,562,972) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
  • 1 fee due Sep 17, 2027
    The maintenance fee for Antibodies Targeting G-Protein Coupled Receptor and Methods of Use (US 10,590,196) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
  • 2 fees due Oct 23 to 28, 2027 · next Oct 23
  • 2 fees due Nov 7 to 14, 2027 · next Nov 7

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,074,000T Cell Receptor-Like Antibodies Specific for a Wti Peptide Presented by HLA-A2
In force
 · High confidence
In forceHigh confidence
US 10,562,972Antibodies Targeting B-Cell Maturation Antigen and Methods of Use
In force
 · Low confidence
In forceLow confidence
US 10,590,196Antibodies Targeting G-Protein Coupled Receptor and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 10,633,426Chimeric Antigen Receptors Targeting G-Protein Coupled Receptor and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,906,956Methods of Treatments Using Chimeric Antigen Receptors Targeting G-Protein Coupled Receptor
In force
 · Medium confidence
In forceMedium confidence
US 10,947,314Antibodies Targeting B-Cell Maturation Antigen and Methods of Use
In force
 · Low confidence
In forceLow confidence
US 11,566,071Nucleic Acid Molecules Encoding ANTI-GPRC5D Antibodies
In force
 · Medium confidence
In forceMedium confidence
US 11,725,059Antibodies Targeting B-Cell Maturation Antigen and Methods of Use
In force
 · Low confidence
In forceLow confidence
US 11,820,806Chimeric Antigen Receptors Targeting G-Protein Coupled Receptor and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 11,866,478Nucleic Acid Molecules Encoding Chimeric Antigen Receptors Targeting G-Protein Coupled Receptor
In force
 · Medium confidence
In forceMedium confidence
10 of 39 patents shown.
Pro members see all 39.
Pro members: see all 39 patents
Also on record, not counted in the 39: 8 patents in force now held by others · 8 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 8 abandoned · 14 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited